Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21802521 | 0.94 | AKR1C3 (0.59) | SMN1; SMN2AKR1C3HRH3HPGDHTR7 | |
| SCHEMBL3013949 | 0.85 | SMN1; SMN2 (0.59) | SMN1; SMN2HRH3HPGDHTTHIF1A | |
| SCHEMBL21802556 | 0.85 | HTR7 (0.53) | HRH3HTR7DRD4 | |
| SCHEMBL27783861 | 0.84 | SMN1; SMN2 (0.58) | SMN1; SMN2AKR1C3HRH3HPGDHTT | |
| SCHEMBL1450838 | 0.84 | HRH3 (0.78) | SMN1; SMN2HRH3HPGDHIF1AEPAS1 | |
| SCHEMBL24462388 | 0.80 | HRH3 (0.71) | SMN1; SMN2AKR1C3HRH3HPGDALDH1A1 | |
| SCHEMBL1722245 | 0.80 | SMN1; SMN2 (0.57) | SMN1; SMN2HRH3HTTCYP2C19ALDH1A1 | |
| SCHEMBL21802554 | 0.80 | SMN1; SMN2 (0.57) | SMN1; SMN2AKR1C3CYP2C9CYP2C19HTR7 | |
| SCHEMBL21802520 | 0.80 | AKR1C3 (0.56) | SMN1; SMN2AKR1C3HRH3HPGDHTT | |
| SCHEMBL29266144 | 0.80 | CHKA (0.64) | HRH3HTR7DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | SMN1; SMN2 4550/4885AKR1C3 397/4885HRH3 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.